With both consensus revenue growth and net profit margin forecasts holding steady, analysts kept their price target for Torrent Pharmaceuticals unchanged at ₹3929.
What's in the News
- Shareholders approved the appointment of Aman Mehta as Managing Director for five years, following his successful tenure as Whole-time Director, where he led growth initiatives, integration of acquisitions, field force expansion, and portfolio revamps.
- Aman Mehta has taken charge of R&D and Operations, achieving sharper business alignment, efficiency gains, and improved margins.
- The company is in advanced negotiations to acquire J.B. Chemicals & Pharmaceuticals from KKR & Co., aiming to consolidate its domestic pharmaceutical market position.
- A Board Meeting was scheduled to consider and approve the acquisition of equity shares of J.B. Chemicals & Pharmaceuticals.
- A Board Meeting was scheduled to consider and approve the audited standalone and unaudited consolidated financial results for the quarter ended 30-Jun-25.
Valuation Changes
Summary of Valuation Changes for Torrent Pharmaceuticals
- The Consensus Analyst Price Target remained effectively unchanged, at ₹3929.
- The Consensus Revenue Growth forecasts for Torrent Pharmaceuticals remained effectively unchanged, at 12.4% per annum.
- The Net Profit Margin for Torrent Pharmaceuticals remained effectively unchanged, at 22.23%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.